Viroclinics Biosciences is a leader in diagnostic and clinical-trial services. It is one of the few labs in the world able to perform highly complex, specialized diagnostic and preclinical studies in the field of virology. Viroclinics operates globally as the preferred virology testing laboratory for top-ten biopharmaceutical companies.

Gilde acquired a majority share in 2013. During Gilde ownership Viroclinics developed new services for the biopharmaceutical industry, expanded its facilities and tripled its revenues. Viroclinics was sold in 2017 to Parcom Capital.